Management of dyslipidemia during pregnancy requires individualized guidance, lifestyle strategies, and targeted pharmacological interventions to optimize maternal and fetal outcomes.
What are the current strategies for managing dyslipidemia during pregnancy?
This review highlights the importance of individualized, multidisciplinary management of dyslipidemia in pregnancy to mitigate ASCVD and pregnancy complication risks.
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). Abnormal maternal lipid profiles in pregnancy are associated with pregnancy complications including preeclampsia, gestational diabetes, and pre-term delivery as well as increased ASCVD risk for both mother and child. Dyslipidemia management remains a central tenet for atherosclerotic cardiovascular disease prevention for women who are thinking about becoming pregnant or are already pregnant. Effective individualized guidance and multidisciplinary lifestyle/dietary strategies, along with targeted pharmacological interventions, are required for the successful management of lipid disorders in pregnancy in order to optimize outcomes. This review discusses the physiological changes occurring in lipid metabolism during pregnancy and provides an overview of the current strategies for managing dyslipidemia during pregnancy, with a special focus on consideration of pharmacological therapy.
Kosmas et al. (Sun,) conducted a review in Dyslipidemia in pregnancy. Dyslipidemia management (lifestyle, dietary, and pharmacological) was evaluated. Management of dyslipidemia during pregnancy requires individualized guidance, lifestyle strategies, and targeted pharmacological interventions to optimize maternal and fetal outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: